Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

NCT05658510 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

452

Enrollment

INDUSTRY

Sponsor class

Conditions

Agitation,Psychomotor
Bipolar I Disorder
Bipolar II Disorder
Schizophrenia
Schizoaffective Disorder
Schizophreniform Disorders

Interventions

DRUG: BXCL501
DRUG: Matching Placebo

Sponsor

BioXcel Therapeutics Inc

Collaborators

[object Object]